跳转到内容

伏立诺他

维基百科,自由的百科全书
伏立诺他
臨床資料
读音/vɒˈrɪnstæt/ vorr-IN-oh-stat
商品名英语Drug nomenclatureZolinza
AHFS/Drugs.comMonograph
MedlinePlusa607050
核准狀況
给药途径Oral (capsules)
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度1.8–11%[1]
血漿蛋白結合率~71%
药物代谢Hepatic glucuronidation and β-oxidation
CYP system not involved
代謝產物vorinostat O-glucuronide, 4-anilino-4-oxobutanoic acid (both inactive)[2]
生物半衰期~2 hours (vorinostat and O-glucuronide), 11 hours (4-anilino-4-oxobutanoic acid)
排泄途徑Renal (negligible)
识别信息
  • N-Hydroxy-N'-phenyloctanediamide
CAS号149647-78-9  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.207.822 編輯維基數據鏈接
化学信息
化学式C14H20N2O3
摩尔质量264.33 g·mol−1
3D模型(JSmol英语JSmol
  • O=C(Nc1ccccc1)CCCCCCC(=O)NO
  • InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18) checkY
  • Key:WAEXFXRVDQXREF-UHFFFAOYSA-N checkY

伏立诺他rINNVorinostat,商品名:Zolinza)是一种含氮有机化合物[3],分子式C14H20N2O3,是一种组蛋白脱乙酰酶抑制劑

参考文献

[编辑]
  1. ^ Withdrawal Assessment Report for Vorinostat MSD 100 mg Hard Capsules (vorinostat) (PDF). European Medicines Agency: 9. 23 October 2008 [1 September 2016]. (原始内容 (PDF)存档于15 September 2016). 
  2. ^ Zolinza (vorinostat) Capsules. Full Prescribing Information (PDF). Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. [1 September 2016]. 
  3. ^ International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 56 (PDF). WHO Drug Information. 2006, 20 (3): 232 [1 September 2016]. (原始内容 (PDF)存档于July 5, 2011). 

外部链接

[编辑]